Stocklytics Platform
Asset logo for symbol ZVRA
Zevra Therapeutics
ZVRA62
$9.58arrow_drop_up4.98%$0.45
High Growth
Asset logo for symbol ZVRA
ZVRA62

$9.58

arrow_drop_up4.98%

Performance History

Chart placeholder
Key Stats
Open$9.24
Prev. Close$9.13
EPS-2.13
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.96
9.63
52 Week Range3.89
9.63
Ratios
EPS-2.13

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Zevra Therapeutics (ZVRA)

KemPharm Inc (ZVRA) is a pharmaceutical company that specializes in the development and commercialization of new treatments for various medical conditions. The company's stock price history has shown both ups and downs over the years, reflecting the volatility of the pharmaceutical industry. Investors interested in KemPharm Inc can keep track of the stock price by checking its quote regularly. This will provide them with the most up-to-date information on its current value. In addition to the stock price, investors can also stay informed about KemPharm Inc through the latest stock news, which includes updates on clinical trials, regulatory approvals, and partnerships.
For a more detailed analysis of KemPharm Inc's stock, investors can refer to the stock analysis reports available. These reports provide insights into the company's financial performance, market trends, and potential growth opportunities. Investors can use this information to make informed decisions about whether to buy, sell, or hold KemPharm Inc stock. It is also helpful to compare KemPharm Inc's performance with others in the industry to gauge its competitiveness. This can be done by comparing its market cap and PEG ratio with industry averages. The market cap reflects the overall value of the company, while the PEG ratio assesses its growth potential relative to its earnings.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Christal M. M. Mickle M.A.
Headquarters
Celebration
Employees
32
Exchange
NASDAQ
add Zevra Therapeutics to watchlist

Keep an eye on Zevra Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Zevra Therapeutics's (ZVRA) price per share?

The current price per share for Zevra Therapeutics (ZVRA) is $9.59. The stock has seen a price change of $0.46 recently, indicating a 4.98% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Zevra Therapeutics (ZVRA)?

For Zevra Therapeutics (ZVRA), the 52-week high is $9.63, which is 0.5% from the current price. The 52-week low is $3.89, the current price is 146.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Zevra Therapeutics (ZVRA) a growth stock?

Zevra Therapeutics (ZVRA) has shown an average price growth of -4.13% over the past three years. It has received a score of 74 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Zevra Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Zevra Therapeutics (ZVRA) stock price performance year to date (YTD)?

As of the latest data, Zevra Therapeutics (ZVRA) has a year-to-date price change of 40.34%. Over the past month, the stock has experienced a price change of 19.66%. Over the last three months, the change has been 33.5%. Over the past six months, the figure is 113.47%.
help

Is Zevra Therapeutics (ZVRA) a profitable company?

Zevra Therapeutics (ZVRA) has a net income of -$46.05M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.28% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -739% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $27.46M, although specific revenue growth data is currently not available. The gross profit is $24.52M. Operating income is noted at -$49.6M. Furthermore, the EBITDA is -$70.83M.
help

What is the market capitalization of Zevra Therapeutics (ZVRA)?

Zevra Therapeutics (ZVRA) has a market capitalization of $511.61M. The average daily trading volume is 9.49, indicating the stock's liquidity and investor engagement.

News

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
ZEVRA THERAPEUTICS
MIPLYFFA
NIEMANN-PICK DISEASE TYPE C
FDA APPROVAL
PATIENT SUPPORT PROGRAM
Nov 21, 2024

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
NIEMANN-PICK DISEASE TYPE C
NPCCSS
SWALLOW DOMAIN
CLINICAL SEVERITY SCALE
ARIMOCLOMOL
Nov 11, 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
NIEMANN-PICK DISEASE TYPE C
ARIMOCLOMOL
FDA ADVISORY COMMITTEE
RARE DISEASE
Aug 2, 2024

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Zevra Therapeutics Expands Executive Leadership Team
DIRECTORS AND OFFICERS
Jun 25, 2024

Zevra Therapeutics Expands Executive Leadership Team

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
PARTNERSHIPS
Jun 18, 2024

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
CALENDAR OF EVENTS
CLINICAL STUDY
Jun 3, 2024

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

Take Your Investments to a Whole New Level